Sanofi trial shows Fluzone high-dose flu vaccine efficacy
PARIS (Reuters) - Sanofi said on Monday that a large clinical trial showed its Fluzone High-Dose vaccine to be more effective at preventing influenza in adults aged 65 and older than a standard dose of Fluzone.
Sanofi said it plans to submit the full clinical study report to the U.S. Food and Drug Administration for review by early 2014 and will seek to modify to the label for Fluzone High-Dose vaccine to reflect the superior efficacy data in this age group.
In the study, which included roughly 30,000 participants, Fluzone High-Dose vaccine was 24.2 percent more effective in preventing influenza in adults 65 years of age and older than Fluzone vaccine.
Fluzone High-Dose vaccine was licensed for sale by the FDA in 2009 under an accelerated approval process that included a requirement that Sanofi complete a large-scale confirmatory study.
(Reporting by Leila Abboud)
- Tweet this
- Share this
- Digg this
- South Africa, world mourn 'giant for justice' Nelson Mandela
- Study casts doubt on whether extra vitamin D prevents disease
- Delhi's rubble-strewn Connaught Place mirrors Congress' election struggle
- U.S. television, Twitter, alive with new version of 'Sound of Music'
- UPDATE 4-Child killed in Idaho school bus accident, 4 more hurt
While focus on the “core” communities has helped keep the disease in check, authorities must “follow the epidemic” and target internal migrants and truckers to widen the scope of prevention efforts, two UNAIDS officials said in an interview with India Insight. Article